Cato you might benefit from reading the LVAD trial conclusions by the researchers from the Cardiothoracic Surgical Trials Network. It is not as simple as the target was not achieved. They learned a number of useful things which are in the Conclusions, including that MPCs ........"may lead to new therapeutic approach"
The market for the product may have grown larger and it may be possible the treatment for these sorts of patients may be applied without needing to do a Phase 3 trial but that is subject to discussions between Mesoblast and the FDA.
The slides from the presentation at the conference are here, thanks @jack123456
The Conclusions part is on slide 15
And that is probably why Bell Potter have not changed their valuation.
Bell Potter valuation, page-15
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |